Treatment of pityriasis rubra pilaris with etanercept

Dermatologic Therapy

Volumn 24, Issue 2, 2011, Pages 285-286

  Guedes, Rita ^a   Leite, Luiz ^b  

^a CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^b Serviço de Dermatologia   (Portugal)

Author keywords

Etanercept; Pityriasis; Rubra

Indexed keywords

CLOBETASOL; ETANERCEPT; ISOTRETINOIN; TUMOR NECROSIS FACTOR ALPHA; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; PITYRIASIS RUBRA PILARIS; SKIN BIOPSY; BIOPSY; DRUG EFFECT; PATHOLOGY; SKIN; TIME; TREATMENT OUTCOME;

ADULT; BIOPSY; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; PITYRIASIS RUBRA PILARIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952769140     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01404.x     Document Type: Article

References (5)

1. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005: 9 (6): 296-302. (Pubitemid 44491079)
2. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003: 7 (5): 382-386. (Pubitemid 37500396)
3. Cox V, Lesesky EB, Garcia BD, O'Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol 2008: 59 (Suppl. 5): S113-S114.
4. Davis KF, Wu JJ, Murase JE, Rosenberg FR, Sorenson EP, Meshkinpour A. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007: 143 (12): 1597-1599. (Pubitemid 350277793)
5. Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol 2008: 158 (3): 642-644. (Pubitemid 351239177)